Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

Herantis Pharma

Herantis Pharma

Developer of disease-modifying treatments

Herantis Pharma is a publicly listed (Finland, HRTIS and Sweden, HRNTS) drug development company aiming to revolutionize the treatment of diseases with unmet clinical needs. Based on leading academic research published in high-impact journals including Nature and Science, two ongoing clinical development programs explore the potential of its novel drug candidates in Parkinson’s disease and secondary lymphedema. Both Parkinson’s disease and lymphedema remain conditions in which current treatments only address symptoms and therefore do not enable long-term improvement for patients.

We believe that Herantis offers an attractive opportunity to address diseases with a large unmet medical need and to compete on the market for neurodegenerative diseases and secondary lymphedema. Additionally, the company’s technology could serve as a platform going into several diseases with similar pathologies. If strong clinical data is generated the company could find itself in an attractive position as an acquisition.

The key risks for Herantis are related to clinical and development risks of its candidates in terms of failed or delayed studies. Liquidity and financing risks are also important to consider, as Herantis is currently a development-stage company with negative cash flow. The competitive landscape could also be significantly different at the time when Herantis’ drug candidates could be approved.

EURm 2019 2020e 2021e
Sales 0 0 36
Sales growth (%) -2,2 -100 N/A
EBITDA -5 -6 30
EBITDA margin (%) -2155,6 0 83,4
EBIT adj -6 -6 29
EBIT adj margin (%) -2655,2 0 81,7
Pretax profit -7 -6 29
EPS rep -1,13 -0,95 4,21
EPS growth (%) -32,9 15,7 542,7
EPS adj -1,13 -0,95 4,21
DPS 0 0 0
EV/EBITDA (x) -10,7 -9,6 0,8
EV/EBIT adj (x) -8,7 -8,4 0,8
P/E (x) -6,9 -7,5 1,7
P/E adj (x) -6,9 -7,5 1,7
EV/sales (x) 230,4 0 0,7
FCF yield (%) -12,1 -10,8 66,1
Dividend yield (%) 0 0 0
Net IB debt/EBITDA 0 -0,9 -0,8
N/A N/A N/A
EURm 2019 2020e 2021e
Sales 0 0 36
COGS 0 0 0
Gross profit 0 0 36
Other operating items -5 -6 -6
EBITDA -5 -6 30
Depreciation on tangibles 0 0 0
Depreciation on intangibles -1 -1 -1
EBITA -6 -6 29
Goodwill impairment charges 0 0 0
Other impairment and amortisation 0 0 0
EBIT -6 -6 29
Other financial items 0 0 0
Net financial items -1 0 0
Associated income 0 0 0
Other EO items 0 0 0
Pretax profit -7 -6 29
Tax 0 0 -1
Net profit -7 -6 28
Minority interest 0 0 0
Net profit discontinued 0 0 0
Net profit to shareholders -7 -6 28
EPS -1,13 -0,95 4,21
EPS Adj -1,13 -0,95 4,21
Total extraordinary items after tax 0 0 0
Tax rate (%) 0 0 -4
Gross margin (%) 100 0 100
EBITDA margin (%) -2155,6 0 83,4
EBITA margin (%) -2655,2 0 81,7
EBIT margin (%) -2655,2 0 81,7
Pretax margin (%) -2910,3 0 81,4
Net margin (%) -2910,3 0 78,2
Growth rates Y/Y 2019 2020 2021
Sales growth (%) -2,2 -100 N/A
EBITDA growth (%) -32,3 -13,5 645,2
EBIT growth (%) -22,7 -4,6 570,7
Net profit growth (%) -56,7 2,9 542,7
EPS growth (%) -32,9 15,7 542,7
Profitability 2019 2020 2021
ROE (%) -404,9 51230,4 234,6
ROE Adj (%) -404,9 51230,4 234,6
ROCE (%) -71,4 -89,4 154,8
ROCE Adj(%) -71,4 -89,4 154,8
ROIC (%) -160,2 -248,6 1043,2
ROIC Adj (%) -160,2 -248,6 1043,2
Adj earnings numbers 2019 2020 2021
EBITDA Adj -5 -6 30
EBITDA Adj margin (%) -2155,6 0 83,4
EBITA Adj -6 -6 29
EBITA Adj margin (%) -2655,2 0 81,7
EBIT Adj -6 -6 29
EBIT Adj margin (%) -2655,2 0 81,7
Pretax profit Adj -7 -6 29
Net profit Adj -7 -6 28
Net profit to shareholders Adj -7 -6 28
Net Adj margin (%) -2910,3 0 78,2
N/A N/A N/A
EURm 2019 2020e 2021e
EBITDA -5 -6 30
Net financial items -1 0 0
Paid tax 0 0 -1
Non-cash items 0 0 0
Cash flow before change in WC -5 -6 29
Change in WC 0 0 3
Operating cash flow -5 -5 32
CAPEX tangible fixed assets 0 0 0
CAPEX intangible fixed assets 0 0 0
Acquisitions and disposals 0 0 0
Free cash flow -5 -5 32
Dividend paid 0 0 0
Share issues and buybacks 10 0 0
Other non cash items 0 0 -3
Decrease in net IB debt 4 -5 29
Balance Sheet (EURm) 2019 2020 2021
Goodwill 0 0 0
Indefinite intangible assets 0 0 0
Definite intangible assets 4 3 2
Tangible fixed assets 0 0 0
Other fixed assets 0 0 3
Fixed assets 4 3 5
Inventories 0 0 0
Receivables 0 0 2
Other current assets 0 0 3
Cash and liquid assets 7 2 31
Total assets 11 5 40
Shareholders equity 3 -3 27
Minority 0 0 0
Total equity 3 -3 27
Long-term debt 7 7 7
Pension debt 0 0 0
Convertible debt 0 0 0
Deferred tax 0 0 0
Other long-term liabilities 0 0 0
Short-term debt 1 1 1
Accounts payable 0 0 5
Other current liabilities 1 1 1
Total liabilities and equity 11 5 40
Net IB debt 0 5 -24
Net IB debt excl. pension debt 0 5 -24
Capital invested 3 2 4
Working capital -1 -1 -1
EV breakdown 2019 2020 2021
Market cap. diluted (m) 52 48 48
Net IB debt Adj 0 5 -24
Market value of minority 0 0 0
Reversal of shares and participations 0 0 0
Reversal of conv. debt assumed equity 0 0 0
EV 52 53 24
Capital efficiency (%) 2019 2020 2021
Total assets turnover (%) 2,5 0 159,1
Capital invested turnover (%) 6 0 1329,3
Capital employed turnover (%) 2,7 0 189,4
Inventories / sales (%) 0 0 0
Customer advances / sales (%) 277,2 0 3,2
Payables / sales (%) 88,7 0 6,8
Working capital / sales (%) -326,5 0 -3,5
Financial risk and debt service 2019 2020 2021
Net debt / equity (%) 0,7 -150,2 -86,3
Net debt / market cap (%) 0 10,6 -49,5
Equity ratio (%) 29,7 -67,1 67,9
Net IB debt adj. / equity (%) 0,7 -150,2 -86,3
Current ratio (%) 523,5 107,7 550,6
EBITDA / net interest (%) -845,1 -5217,7 28448,4
Net IB debt / EBITDA (%) -0,5 -91,4 -78,6
Interest cover (%) -970,7 -5924,3 27883,1
N/A N/A N/A
EURm 2019 2020e 2021e
Capex intangibles / definite intangibles 0 0 0
Depreciation on intangibles / definite intangibles 27,6 25 25
Depreciation on tangibles / tangibles 0 0 0
Shares outstanding adj. 7 7 7
Fully diluted shares Adj 7 7 7
EPS -1,13 -0,95 4,21
Dividend per share Adj 0 0 0
EPS Adj -1,13 -0,95 4,21
BVPS 0,5 -0,5 4,09
BVPS Adj -0,11 -0,95 3,74
Net IB debt / share 0 0,8 -3,5
Share price 7,92 7,14 7,14
Market cap. (m) 53 48 48
Valuation 2019 2020 2021
P/E -6,9 -7,5 1,7
EV/sales 230,39 0 0,67
EV/EBITDA -10,7 -9,6 0,8
EV/EBITA -8,7 -8,4 0,8
EV/EBIT -8,7 -8,4 0,8
Dividend yield (%) 0 0 0
FCF yield (%) -12,1 -10,8 66,1
P/BVPS 15,59 -14,23 1,74
P/BVPS Adj -69,73 -7,53 1,91
P/E Adj -6,9 -7,5 1,7
EV/EBITDA Adj -10,7 -9,6 0,8
EV/EBITA Adj -8,7 -8,4 0,8
EV/EBIT Adj -8,7 -8,4 0,8
EV/cap. employed 5 14,4 0,7
Investment ratios 2019 2020 2021
Capex / sales 0 0 0
Capex / depreciation 0 0 0
Capex tangibles / tangible fixed assets 0 0 0
N/A N/A N/A

Equity research

Read earlier research

Main shareholders - Herantis Pharma

Main shareholders Share capital % Voting shares % Verified
Swedbank Robur Fonder 9.8 % 9.8 % 31 Aug 2020
Inveni Capital 7.0 % 7.0 % 5 Aug 2020
University of Helsinki Funds 6.8 % 6.8 % 5 Aug 2020
Innovestor Kasvurahasto I Ky 5.6 % 5.6 % 5 Aug 2020
OP Fonder 5.6 % 5.6 % 5 Aug 2020
Fjärde AP-fonden 4.5 % 4.5 % 5 Aug 2020
Veritas Pension Insurance Company 4.0 % 4.0 % 5 Aug 2020
Ilmarinen Mutual Pension Insurance Company 3.1 % 3.1 % 5 Aug 2020
Nordea Fonder 3.1 % 3.1 % 5 Aug 2020
Säästöpankki Fonder 3.0 % 3.0 % 31 Aug 2020
Source: Holdings by Modular Finance AB

Insider list - Herantis Pharma

Name Quantity Code Date
Ingrid Atteryd Heiman - 4 584 SELL 18 Sep 2020

Show More